Publications by authors named "E Thebaud"
Background And Aims: Primary lung tumors (PLTs) in children are rare, and surgery remains the key to ensure remission. Here we describe the PLTs clinical characteristics, their management, and the pulmonary outcome following surgery.
Methods: We carried out a French national cohort of pediatric PLTs from 2013 to 2023 from the FRACTURE rare pediatric tumors national database.
Article Synopsis
- - The Ewing Sarcoma Family of Tumors (ESFT) includes rare cancers, with a significant portion showing metastatic spread, especially affecting bone and bone marrow, which worsens prognosis and necessitates stronger treatments.
- - The French phase II COMBINAIR3 study compared the effectiveness of PET/CT to traditional bone marrow aspiration and biopsy (BMAB) for staging extra-pulmonary metastatic ESFT in 42 patients.
- - Results indicated that PET/CT had high specificity (100%) and notable sensitivity (83.3%) in detecting bone marrow involvement, suggesting it can replace BMAB for initial staging, thereby enhancing treatment planning for high-risk ESFT patients.
Introduction: Introduction: Renal cell carcinoma (RCC) is a very rare pediatric renal tumor. Robust evidence to guide treatment is lacking and knowledge on targeted therapies and immunotherapy is mainly based on adult studies. Currently, the International Society of Pediatric Oncology-Renal Tumor Study Group (SIOP-RTSG) 2016 UMBRELLA protocol recommends sunitinib for metastatic or unresectable RCC.
View Article and Find Full Text PDFBackground: Adult- and adolescent-onset neuroblastomas are rare, with no established therapy. In addition, rare pheochromocytomas may harbor neuroblastic components. This study was designed to collect epidemiological, diagnostic and therapeutic data in order to better define the characteristics of malignant peripheral neuroblastic tumors (MPNT) and composite pheochromocytomas (CP) with MPNT.
View Article and Find Full Text PDFBackground: Addition of anti-GD2 antibodies to temozolomide-based chemotherapy has demonstrated increased antitumor activity and progression-free survival in patients with relapsed/progressive high-risk neuroblastoma. However, chemo-immunotherapy is not yet approved for this indication. This study presents the chemo-immunotherapy experience in patients with relapsed/progressive high-risk neuroblastoma treated within the off-label use program of the Neuroblastoma Committee of the French Society of Pediatric Oncology (SFCE).
View Article and Find Full Text PDF